AirNexis Therapeutics
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
AirNexis Therapeutics Launches with $200M Series A
AirNexis Therapeutics has emerged from stealth with $200 million in Series A financing to advance a novel therapy for chronic obstructive pulmonary disease (COPD).
The round was led by Frazier Life Sciences with participation from OrbiMed, SR One, Goldman Sachs, Longitude Capital, and Enavate Sciences.
Key Highlights
- One of the largest Series A rounds in biotech
- Novel dual PDE3/4 inhibitor for COPD
- Combines bronchodilation and inflammation reduction
Company Overview
AirNexis Therapeutics is developing a dual PDE3/4 inhibitor that combines bronchodilation with anti-inflammatory effects, potentially offering COPD patients a more effective treatment option.
Company Info
Investors (4)
Share
Related Reports
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Ema Raises $77M Series B to Expand Its Enterprise AI Employee Platform
Ema raised a $77 million Series B led by Creaegis, bringing total funding to $140 million as it scales AI agents across enterprise workflows.
Chamelio Raises $26M Series A for AI-Native Legal Operations
Chamelio raised a $26 million Series A led by Entrée Capital to replace legacy contract-management systems with agentic legal operations.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free